Endometrial cancer is among the most common malignancies of the female reproductive system, and its global incidence has climbed markedly in recent years. Roughly ninety percent of cases are caught early and respond well to surgery and chemoradiotherapy, but patients with locally advanced, recurrent, or metastatic disease often resist standard treatment and face poor outcomes. That clinical gap has pushed researchers to hunt for the molecular drivers that separate indolent tumors from aggressive ones. The new study focuses on the epitranscriptome, the layer of chemical modifications deposited onto RNA after transcription, which has emerged in the past decade as a major regulator of gene expression in health and disease.

Among these modifications, 5-methylcytosine, abbreviated m5C, is one of the most abundant marks on eukaryotic messenger RNA. Like other RNA modifications, m5C operates through a cast of enzymes and binding proteins: writer enzymes such as NSUN2 and NSUN6 install the methyl group, erasers can remove it, and reader proteins such as ALYREF recognize the mark and determine what happens to the tagged transcript. ALYREF, historically known for its role in ferrying mature mRNA out of the nucleus, binds m5C-modified sites and influences RNA stability, export, and metabolic fate. Previous work had implicated ALYREF in nasopharyngeal carcinoma, glioma, lung cancer, and bladder cancer, but its role in endometrial cancer remained uncharted.

The team began by mining several independent public datasets, including the Gene Expression Omnibus, The Cancer Genome Atlas, GTEx, and the Human Protein Atlas. Across every source, ALYREF was significantly elevated in tumor tissue compared with normal endometrium, at statistical thresholds below p = 0.001. The pattern held in paired comparisons of tumors and adjacent normal tissue from the same patients, and immunohistochemistry on clinical specimens confirmed the protein-level difference. Most strikingly, survival analysis of the TCGA endometrial carcinoma cohort showed that patients with high ALYREF expression had significantly shorter overall survival and relapse-free survival, and multivariate Cox regression established ALYREF as an independent prognostic factor after adjustment for clinicopathological variables. High ALYREF also tracked with aggressive histology, including grade 3 tumors and serous or mixed subtypes.

To test whether ALYREF actively drives the disease rather than merely marking it, the researchers manipulated its expression in endometrial cancer cell lines. Silencing ALYREF with short hairpin RNAs in HEC-1A and Ishikawa cells, which naturally express the protein at high levels, sharply reduced colony formation, cell proliferation measured by CCK-8 assays, and DNA synthesis measured by EdU incorporation. Wound healing and Transwell experiments showed impaired migration and invasion, while flow cytometry revealed G2/M cell cycle arrest and increased apoptosis. Conversely, forcing ALYREF expression in KLE cells, which normally produce little of the protein, enhanced every one of those malignant behaviors. In nude mice bearing subcutaneous xenografts, ALYREF knockdown significantly slowed tumor growth, reducing both tumor volume and final tumor weight over a 42-day observation period.

The mechanistic hunt began with an unbiased, three-pronged sequencing strategy. RNA sequencing of ALYREF-knockdown cells identified 1,890 differentially expressed genes. RNA immunoprecipitation sequencing captured 703 transcripts physically bound by ALYREF. And bisulfite sequencing tailored to detect m5C mapped 4,084 modified transcripts, revealing that the marks cluster mainly within the coding sequence of mRNAs. Intersecting all three datasets narrowed the field to 28 candidate targets, and among the ten most downregulated after ALYREF depletion, one gene stood out: XRCC6, which encodes the Ku70 subunit of the non-homologous end joining DNA repair complex. The correlation was robust at every level, from a Pearson coefficient of 0.749 between ALYREF and XRCC6 mRNAs in the TCGA cohort to a Spearman coefficient of 0.82 between the two proteins in 50 clinical tumor samples.

Rescue experiments then confirmed that XRCC6 is the functional effector of ALYREF. Restoring XRCC6 expression in ALYREF-deficient cells reversed nearly every malignant phenotype: proliferation recovered, migration and invasion returned, G2/M arrest eased, and apoptosis subsided. In xenografted mice, XRCC6 overexpression largely canceled the tumor-suppressive effect of ALYREF knockdown. The regulation itself proved to be a matter of mRNA stability rather than export. Actinomycin D chase assays showed that XRCC6 mRNA degraded much faster without ALYREF, its half-life shrinking significantly, while nuclear-cytoplasmic fractionation demonstrated that cytoplasmic levels of the transcript fell even as nuclear levels stayed constant, indicating that ALYREF protects the mRNA in the cytoplasm rather than shuttling it out of the nucleus.

The epitranscriptomic logic of the axis came into focus through experiments on the writer enzymes. When NSUN2 was silenced, XRCC6 mRNA levels dropped; knocking down NSUN6 had no effect. Crucially, in cells lacking NSUN2, additional depletion of ALYREF produced no further reduction in XRCC6, showing that the methyl mark is a prerequisite for ALYREF’s action. Bisulfite sequencing and integrative genomics viewer analysis revealed distinct m5C peaks on the XRCC6 transcript that overlapped precisely with ALYREF binding regions. Reporter assays drove the point home: mutating the methylated sites abolished ALYREF’s suppressive effect on luciferase activity driven by the XRCC6 sequence. Mutating either of two adjacent m5C sites in the coding region partially weakened ALYREF binding and mRNA stability, but mutating both together caused a synergistic collapse, suggesting the two sites operate cooperatively as a local recognition module, a model the authors note will require structural biology to fully confirm.

Downstream, the chain terminates at Wnt/β-catenin signaling, a pathway central to development and frequently hijacked in cancer. ALYREF knockdown drained β-catenin from the nucleus of HEC-1A cells and reduced levels of the Wnt target c-Myc, while XRCC6 overexpression restored both. Notably, co-immunoprecipitation found no direct physical interaction between XRCC6 and β-catenin, implying that XRCC6, a multifunctional nuclear protein, promotes β-catenin transcriptional output indirectly, perhaps by shaping nuclear co-activator complexes or chromatin accessibility. TOP/FOP Flash reporter assays confirmed that XRCC6 boosts β-catenin/TCF-dependent transcription, and canonical Wnt target genes such as AXIN2 and CCND1 fell when ALYREF was silenced. The decisive experiment used XAV-939, a pharmacological Wnt inhibitor: the drug largely blocked the proliferative rescue that XRCC6 overexpression conferred on ALYREF-deficient cells, proving the oncogenic phenotype depends on intact Wnt signaling.

The authors are candid about the study’s limits. Clinical protein validation relied on a single-center retrospective cohort of modest size, the cell line models do not capture the full genomic heterogeneity of TCGA molecular subtypes such as POLE-ultramutated or mismatch-repair-deficient tumors, and the work examined cell-autonomous regulation without probing interactions with cancer-associated fibroblasts or immune cells. Even so, the findings delineate a complete oncogenic axis, ALYREF to m5C to XRCC6 to Wnt/β-catenin, and broaden a growing picture in which ALYREF’s downstream targets differ sharply from one cancer type to another. Because XRCC6 plays dual roles in DNA damage repair and Wnt signaling, patients whose tumors show high ALYREF/XRCC6 expression might ultimately benefit from therapies aimed at either pathway, an idea that now rests on a solid mechanistic foundation and awaits prospective, multicenter testing.

Subject of Research: The role of the m5C reader protein ALYREF in promoting endometrial cancer progression through XRCC6-mediated Wnt/β-catenin signaling

Article Title: m5C Reader ALYREF Promotes the Progression of Endometrial Cancer by Activating the XRCC6‐Mediated Wnt/β‐catenin Signaling Pathway

Article References: Hao, L., Zhang, J., Qian, Q., Jiang, M., Liu, Y., Geng, Y., Cui, N., Guo, Q., & Guo, J. (2026). m 5 C Reader ALYREF Promotes the Progression of Endometrial Cancer by Activating the XRCC6‐Mediated Wnt/β‐catenin Signaling Pathway. Advanced Science, Article e77548. https://doi.org/10.1002/advs.77548

Image Credits: AI Generated

DOI: 10.1002/advs.77548

Keywords: endometrial cancer, ALYREF, m5C, epitranscriptomics, XRCC6, Wnt/β-catenin signaling, NSUN2, RNA modification, mRNA stability, Ku70, prognostic biomarker, Advanced Science

Ionizing radiation kills cells primarily by generating DNA double-strand breaks, the most lethal form of genetic damage. Cells respond with two principal repair strategies: homologous recombination, which operates in the S and G2 phases of the cell cycle and uses an intact sister chromatid as a template, and non-homologous end joining, which is available throughout the cell cycle and directly ligates broken DNA ends. The Ku heterodimer, composed of the Ku70 and Ku80 proteins, sits at the very front line of non-homologous end joining. It recognizes broken DNA ends within seconds of their formation, encircles the free DNA terminus like a sliding clamp, and recruits the downstream enzymatic machinery needed to process and rejoin the break. Without Ku, double-strand breaks accumulate, chromosomal aberrations multiply, and cells become exquisitely sensitive to radiation.

The new research reveals that the assembly of the Ku70-Ku80 heterodimer itself is not a spontaneous, unregulated event but a process actively promoted by a complex containing TIMELESS and SIRT1. TIMELESS, best known for its role in maintaining circadian clocks and stabilizing replication forks, had previously been implicated in the DNA damage response, but its precise contribution to double-strand break repair remained murky. The study now positions TIMELESS as a scaffold that brings together SIRT1 and Ku70, creating a microenvironment in which Ku70 is kept in a state favorable for pairing with its partner Ku80. SIRT1, an NAD-dependent deacetylase, modifies Ku70 by removing acetyl groups, a chemical change that appears to facilitate the proper folding and interaction of Ku70 with Ku80 and with damaged DNA.

Using a combination of co-immunoprecipitation, proximity ligation assays, and live-cell imaging of DNA repair factor recruitment, the investigators demonstrated that cells lacking TIMELESS or SIRT1 show a marked deficit in Ku heterodimer formation. When the researchers depleted TIMELESS, Ku70 failed to associate efficiently with Ku80, and the recruitment of Ku to laser-induced DNA damage tracks was visibly delayed. The same phenotype emerged when SIRT1 was inhibited pharmacologically or knocked down genetically, indicating that the deacetylase activity of SIRT1 is a functional requirement, not merely a passive component of the complex. Rescue experiments in which wild-type SIRT1 was reintroduced restored Ku assembly, whereas catalytically inactive SIRT1 mutants did not, pinpointing the enzymatic activity as the decisive factor.

The consequences for radiation sensitivity were striking. Cancer cells deficient in TIMELESS or SIRT1 accumulated more residual double-strand breaks after irradiation, displayed elevated levels of chromosome breaks and micronuclei, and died at substantially higher rates following clinically relevant doses of radiation. Conversely, cells engineered to overexpress the TIMELESS-SIRT1-Ku70 module became more resistant, repairing radiation-induced breaks faster and surviving doses that killed their normal counterparts. The effect was specific to the Ku pathway: markers of homologous recombination were largely unaffected, suggesting that the complex operates selectively on non-homologous end joining rather than globally boosting all forms of DNA repair.

What makes this discovery particularly compelling is the cast of characters involved. SIRT1 has long fascinated biologists because of its links to calorie restriction, aging, and metabolism, and pharmacological SIRT1 activators have been pursued as potential anti-aging therapeutics. TIMELESS connects the study to the circadian clock, raising the tantalizing possibility that the daily rhythm of a cell’s repair capacity may be governed, at least in part, by the oscillating availability of this complex. Clinicians have long observed that the timing of radiotherapy within the day can influence outcomes in some cancers, and a molecular bridge between clock proteins and DNA repair machinery offers a plausible mechanistic underpinning for such observations. If TIMELESS abundance or activity fluctuates with the cell’s internal clock, the efficiency of Ku assembly, and therefore of end joining, might fluctuate with it.

For oncology, the immediate implication is that the TIMELESS-SIRT1-Ku70 axis represents a candidate target for radiosensitization. Drugs that disrupt the complex, inhibit SIRT1’s deacetylase activity in tumors, or prevent the recruitment of Ku to broken DNA could strip cancer cells of a key survival advantage and make radiation therapy more effective at lower doses. This matters because dose escalation is often limited by damage to surrounding healthy tissue; a radiosensitizer that preferentially compromises tumor cell repair would widen the therapeutic window. The study’s demonstration that SIRT1 inhibition phenocopies TIMELESS loss is especially encouraging from a translational standpoint, since SIRT1 inhibitors already exist as research tools and are being explored in other disease contexts.

The findings also carry a cautionary note for interpreting tumor biology. High levels of TIMELESS have been reported in several malignancies and have been associated with poor prognosis, an observation often attributed to the protein’s role in supporting replication stress tolerance and cell proliferation. The new work adds a second, complementary explanation: tumors that overexpress TIMELESS may also be intrinsically more resistant to radiotherapy because their Ku assembly machinery runs at full throttle. This could help explain why some patients with seemingly similar tumors respond dramatically differently to the same radiation regimen, and it suggests that TIMELESS expression levels might serve as a biomarker for predicting radiosensitivity and guiding treatment decisions.

As with any mechanistic study, important questions remain. The precise structural details of how TIMELESS docks onto Ku70 and how SIRT1’s deacetylation of Ku70 alters the heterodimer’s DNA-binding properties will require biochemical and structural characterization. It is also not yet clear whether the complex acts at the break site itself or in the nucleoplasm before Ku ever encounters damaged DNA, and whether additional factors participate in the assembly process. Translating the findings into the clinic will demand evidence that the axis operates in human tumors in vivo and that its disruption does not catastrophically sensitize normal tissues, which also rely on Ku-mediated repair to survive radiation. Nonetheless, by illuminating a previously hidden regulatory step in one of the cell’s most fundamental repair pathways, the study opens a concrete new avenue for making radiation therapy work harder against cancer, and it reinforces a growing theme in modern oncology: the most effective treatments may come not from hitting tumors harder, but from quietly dismantling the molecular machinery that lets them endure.

Subject of Research: A TIMELESS-SIRT1-Ku70 protein complex that promotes Ku heterodimer assembly and confers radioresistance to cancer cells through enhanced non-homologous end joining DNA repair.

Article Title: A TIMELESS-SIRT1-Ku70 complex confers radioresistance to cancer cells by promoting Ku heterodimer assembly

Article References: A TIMELESS-SIRT1-Ku70 complex confers radioresistance to cancer cells by promoting Ku heterodimer assembly. (n.d.). https://doi.org/10.1038/s41420-026-03363-w

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03363-w

Keywords: TIMELESS, SIRT1, Ku70, Ku80, DNA double-strand breaks, non-homologous end joining, radioresistance, radiation therapy, DNA repair, circadian clock, cancer, radiosensitization